ChemoCentryx Inc expected to post a loss of 30  cents a share - Earnings Preview

Churchill Capital XI

04/05/2022 03:01

* ChemoCentryx Inc  CCXI.OQ   CCXI.O  is expected to show a
rise
in quarterly revenue when it reports  results on May 5. 
    * The San Carlos California-based  company is expected to
report 
a 112.9% increase in revenue to $22.04 million from $10.35
million a year ago, according to the mean estimate from 7
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for ChemoCentryx Inc is
for a
loss of 30 cents per share. For the same quarter last year, the
company reported a loss of 43 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 15.6%
in the last three months. ​
    * Wall Street's median 12-month price target for
ChemoCentryx Inc
is $65​, above​ its last closing price of $17.68. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -0.60       -0.58      -0.58     Met     0.6
 Sep. 30 2021  -0.44       -0.45      -0.32     Beat    28.3
 Jun. 30 2021  -0.54       -0.54      -0.56     Missed  -2.8​
 Mar. 31 2021  -0.42       -0.40      -0.43     Missed  -6.2
 ​​Dec.        -0.34       -0.33      -0.43     Missed  -29.2
 31 2020                                                
 Sep. 30 2020  -0.31       -0.31      -0.35     Missed  -12.4​
 Jun. 30 2020  -0.34       -0.34      0.29      Beat    185.3
 Mar. 31 2020  -0.30       -0.30      -0.35     Missed  -16.7
 This summary was machine generated May 4 at 02:00 GMT.  All
figures in US dollars  unless otherwise stated